Naprorex (Naproxen)

Naproxen works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. Lower prostaglandin levels lead to decreased inflammation, pain perception, and fever generation.

The appropriate dose of Naprorex is determined by a qualified prescriber based on the individual’s medical condition, age, weight, and response to therapy. Patients should follow the dosing instructions provided on the prescription label.

Naproxen is generally avoided in the third trimester of pregnancy because of potential risks to the fetus. Use during the first two trimesters should only be considered if the benefit outweighs the risk and under medical supervision. Limited data are available for breastfeeding, so a healthcare professional should be consulted.

To place an order, submit an enquiry on the Naprorex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both naproxen (Naprorex) and ibuprofen belong to the NSAID class and share similar mechanisms of COX inhibition. Naproxen has a longer half‑life, allowing less frequent dosing, while ibuprofen may have a slightly faster onset. Safety profiles are comparable, but individual patient factors such as gastrointestinal or cardiovascular risk guide the choice.

Naprorex should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and keep them out of reach of children.

Naprorex is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food or milk may reduce stomach irritation. Patients should swallow the tablet whole and not crush or chew it.

Serious risks include gastrointestinal bleeding or ulcer perforation, severe renal impairment, hepatic injury, cardiovascular events such as heart attack or stroke, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms occur.

Naprorex should be avoided by individuals with a known hypersensitivity to naproxen or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic disease, uncontrolled hypertension, and women in the third trimester of pregnancy. A healthcare professional should evaluate all contraindications before prescribing.